Targeting pandemic influenza: a primer on influenza antivirals and drug resistance | Zendy

Ronald B. Moss | Zendy; Richard T. Davey | Zendy; Roy T. Steigbigel | Zendy; Fang Fang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting pandemic influenza: a primer on influenza antivirals and drug resistance

Author(s) -

Ronald B. Moss,

Richard T. Davey,

Roy T. Steigbigel,

Fang Fang

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq100

Subject(s) - pandemic , virology , drug resistance , influenza a virus , virus , population , influenza pandemic , biology , drug development , drug , medicine , covid-19 , infectious disease (medical specialty) , microbiology and biotechnology , disease , environmental health , pharmacology , pathology

The emergence of the 2009 H1N1 pandemic influenza A virus, as well as constant antigenic drift of seasonal influenza, underscores the remarkable versatility of this virus in adapting to the human population. While vaccines are the principal public health defence against influenza, rapid vaccine development can be a daunting task. Antiviral drugs offer the promise of inhibiting influenza regardless of its genetic variations. However, the rapid rise of resistance to several antivirals has highlighted the need for developing novel therapeutics with reduced drug resistance potential. In this review, we will summarize the effects of the currently licensed anti-influenza drugs as well as the candidates in development against the seasonal and the 2009 H1N1 pandemic influenza A virus with an emphasis on drug resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research